Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies

NCT07636486 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Luspatercept
Epoetin
Poor Erythroid Engraftment
Hematological Malignancies

Interventions

DRUG: Luspatercept
DRUG: Epoetin

Sponsor

Nanfang Hospital, Southern Medical University